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1. Introduction  
Pediatric brain tumors are more complex disorders than other cancers due to gaps in our 
understanding of their cellular origins, insufficient drug therapy, and complications arising 
from the blood brain barrier. Nevertheless, in the last decade, there has been significant 
improvement in the treatment of these tumors although the survival rate is still low. Thus, 
new innovative approaches to treat these malignant tumors are warranted. Among pediatric 
brain tumors, medulloblastoma is the most common and contributes significantly to the 
high mortality rate among children throughout the world. Defects in Sonic Hedgehog (Shh) 
signal transduction are major contributors to brain tumor development, especially 
medulloblastoma. In this book chapter, we review recent publications that identified new 
Shh downstream target genes that are implicated in medulloblastoma development. The 
products of these genes represent novel therapeutic targets that might lead to innovative 
approaches to treat brain tumors. 
2. Medulloblastoma biogenesis 
Medulloblastoma is a member of the family of cranial primitive neuroectodermal tumors 
(PTEN) (Wechsler-Reya and Scott, 2001). Medulloblastoma cells are small, round, 
undifferentiated cells that are often located near the cerebellum. Their morphological 
properties and physical location are most consistent with cerebellar granule neuron 
precursor (GNPs), and thus, medulloblastomas are believed to originate from transformed 
GNPs that have failed to differentiate and continue to proliferate (Wechsler-Reya and Scott, 
2001). For example, mutations in the Shh signaling pathway lead to persistent GNP 
proliferation and a failure to differentiate and ultimately medulloblastoma development 
(Wechsler-Reya and Scott, 2001). However, tumor biogenesis is a complex process that 
involves many genes and signaling pathways and recent studies indicate that subtypes of 
medulloblastoma have distinct molecular and cellular origins. For instance, mutations in the 
Wnt pathway lead to a discrete subtype of medulloblastoma that arise outside of the 
cerebellum (Gibson et al., 2010). Therefore, it is very difficult to treat tumors with one drug 
or pathway inhibitor. Furthermore, Shh signal transduction is important for a wide variety 
of cellular processes during normal development; therefore, drugs that interfere with Shh 
signal transduction might lead to neurodevelopmental defects. In addition, Shh downstream 
target genes are cross-regulated by multiple, independent pathways including Notch and 
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Wnt pathways. Thus, developing novel therapeutics to downstream target genes allows the 
ability to inhibit selectively multiple signal transduction pathways, to provide added 
efficacy in disease treatment, and to ameliorate possible deleterious side effects associated 
with inhibition of Shh signal transduction in normal development. 
2.1 Sonic hedgehog signal transduction pathway 
Binding of Shh to the Patched (Ptch1) receptor relieves the inhibition of another 
transmembrane receptor Smoothened (Smo) (Ingham and McMahon, 2001) (Figure 1). Upon 
Smo activation, members of the Gli family of transcription factors translocate to the nucleus 
and bind to the promoter of many target genes such as Ptch1, D Cyclins, and Nmyc (Browd 
et al., 2006; Yoon et al., 2002). In the cerebellum, Shh is produced by Purkinje neurons to 
promote proliferation of GNPs during the first week of postnatal development (Wechsler-
Reya and Scott, 1999). Shh signalling regulates proliferation of GNPs in part via expression 
of Nmyc (Kenney et al., 2003; Knoepfler et al., 2002; Oliver et al., 2003). Mutations in the Shh 
signal transduction pathway are thought to underlie the etiology of medulloblastoma that 
arise from transformed GNPs that fail to cease proliferation during development (Wechsler-
Reya and Scott, 2001). For example, mice with a heterozygous deletion of the Shh negative 
regulator Ptch1 develop tumors that resemble human medulloblastomas (Goodrich et al., 
1997). The focus of this book chapter is the discovery of new Shh downstream target genes 
that are implicated in medulloblastoma development. 
 
 
Fig. 1. The Sonic Hedgehog Signal Transduction Pathway 
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2.2 Cancer stem cell hypothesis 
Current research suggests that a small subset of cells within the tumor mass with the 
capability of tumor regeneration persist even after aggressive therapies including surgery, 
radiation, and chemotherapy. These cells behave like stem cells and are hypothesized to be 
tumor stem cells (TSCs) with renewal capacity (Singh et al., 2004). Therefore, the current 
outlook supports the need for new approaches to target these TSCs for complete tumor 
eradication or at least to overcome tumor recurrence and increase the survival of the patient. 
A complete understanding of the biology of TSCs and the genes and pathways involved is 
vital towards the development of novel therapeutics to treat brain tumors. It has been 
reported that Oct-4, BMP (bone morphogenic protein), Janus family kinase, Notch, Shh and 
Wnt signaling regulate stem cell renewal (Taipale and Beachy, 2001). Among these 
pathways, Shh is thought to be the major contributor to brain tumor development, 
especially medulloblastoma, and Shh shows crosstalk with multiple stem cell renewal 
pathways including Wnt and Notch (Sengupta et al., 2007) (Figure 2), suggesting that 
mutations in the Shh pathway might lead to the development of TSCs and ultimately 
tumorigenesis. Indeed, a recent report has shown that a subset of medulloblastoma cells 
derived from Ptch1 heterozygous mice are cancer stem cells, which are capable of initiating 
and propagating tumors (Ward et al., 2009). However, the exact mechanism of how TSCs are 
regulated by Shh signaling is not well explored. This book chapter will review mechanisms 
of newly identified Shh downstream target genes in stem cell biology to provide insight into 
the role in medulloblastoma biogenesis. 
 
 
Fig. 2. Crosstalk between Sonic Hedgehog, Wnt, and Notch signal transduction pathways 
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3. Transcription factors implicated in Sonic Hedgehog Signal Transduction in 
Neural Tube 
Pax6 and Nkx2.2 are homeobox transcription factors and their involvement within the Shh 
signaling pathway is well defined in the development of the neural tube (Briscoe et al., 
2000); however, their role has only recently been explored in brain tumor development. 
Interestingly, both Pax6 and Nkx2.2 are targets of the major Shh downstream transcription 
factor Gli1 in medulloblastoma cell lines and tissues (Shahi et al., 2010). Moreover, both 
genes have been implicated in stem cell maintenance (Hu et al., 2009; Zhang et al., 2010); 
therefore, it would be fruitful to understand these genes in the context of Shh signaling in 
TSC-mediated medulloblastoma biogenesis.  
3.1 Nkx2.2 
Nkx2.2 (also known as NKX2B and NKX2-2) is a member of the homeobox transcription 
factor family NK-2 originally identified in Drosophila (Kim and Nirenberg, 1989). The Nk-2 
homeodomain transcription factor family has four members: Nkx2.1, Nkx2.1, Nkx2.3 and 
Nkx2.5. These transcription factors show specific binding to the consensus sequence 
T(C/T)AAGTG (Chen and Schwartz, 1995; Tsao et al., 1994), a unique feature compared 
with other homeodomain proteins. The Nk-2 transcription factor family is defined by three 
domains which are conserved in all members: a)  Homeodomain: 60 amino acid, helix-turn-
helix motif, binds to DNA; b) Transcriptional repressor-domain (TN-domain): located at the 
N-terminal region of the protein; and c) Nk-2 specific domain (Nk2-SD):  located at the C-
terminal region of the protein (Lints et al., 1993). Nkx2.2 is a nuclear transcription factor and 
transport into the nucleus is mediated by nuclear localization signals (NLS) of which Nkx2.2 
has two located within the homeodomain (Hessabi et al., 2000). 
3.1.1 Role of Nkx2.2 in nervous system development 
The role of Nkx2.2 during patterning of the ventral neural tube is well defined. Nkx2.2 is 
expressed in a gradient induced by Shh signaling to facilitate the subdivision of the ventral 
neural tube into five progenitor domains: p0, p1, p2, pMN (motor neuron) and p3 (Briscoe et 
al., 2000). It has been shown that the Gli transcriptional activator binds to the enhancer 
region of Nkx2.2 in differentiating neural progenitors (Vokes et al., 2007). Interestingly, 
another homeodomain transcription factor, Pax6 (discussed below), is modulated by Shh 
signaling to define ventral neural tube progenitor cell fate and it is repressed by Nkx2.2 at 
the boundary of pMN and p3 (Briscoe et al., 2000). After the establishment of ventral neural 
progenitor cell fate, expression of both homeodomain transcription factors Pax6 and Nkx2.2 
is maintained to promote the transition of neural progenitors to specific types of postmitotic 
neurons:  vo, v1, v2, MN and v3 (Briscoe et al., 2000). However, this stage of development is 
independent of the Shh target transcription factors Gli1 and Gli2, suggesting that later stages 
of Shh signaling act through other transcription factors (Ding et al., 1998).  
3.1.2 Role of Nkx2.2 in brain cancer 
Nkx2.2 transcription factor expression was surveyed in astrocytic and oligodendroglial 
tumors of low to high grade (Riemenschneider et al., 2004). In general, Nkx2.2 expression 
was high in the low grade tumors (class II and III - anaplastic astrocytoma) compared to 
high grade glioblastoma multiforme (class IV-GBM) (Riemenschneider et al., 2004). Nkx2.2 
is also expressed in medulloblastoma cell lines and primary tumor samples and Nkx2.2 
www.intechopen.com
 Transcription Factor Targets as Treatment for Medulloblastoma 
 
213 
expression is dependent on Shh-Gli1 pathway (Shahi et al., 2010). Upon knockdown of Gli1 
in medulloblastoma cell line with short interfering RNAs (siRNA), Nkx2.2 expression was 
reduced compared to control negative siRNA treated cells (Shahi et al., 2010), suggesting 
that Gli1 positively regulates Nkx2.2 expression. The expression pattern of Nkx2.2 in 
astrocytoma samples was found to be present in most of the astrocytoma cell lines while 
expression in tumor samples was low or absent except for some low grade (class III) 
astrocytoma tumor samples (Shahi et al., 2010). This high expression of Nkx2.2 in some of 
the low grade astrocytoma tumor samples is consistent with previous results of 
Riemenschneider and colleagues. In contrast, knockdown of Gli1 in the high grade 
astrocytoma cell line U87MG showed no change in expression pattern compared to control 
cells (Shahi et al., 2010), suggesting that other signaling pathways or transcription factors 
regulate expression of Nkx2.2 in astrocytoma. The expression of Nkx2.2 was low in the 
majority of neuroblastoma cell lines analyzed (72%) compared to normal control cells (Shahi 
et al., 2011).  
3.1.3 Role of Nkx2.2 in stem cells 
The origin and progression of brain tumors is a complex process that is not very well 
understood.  However, recent advances in tumor biology research suggest that the tumor 
mass originates from a small number of atypical stem cells called TSCs. TSC renewal is 
regulated by many pathways including BMP, Notch, Shh and Wnt (Ponnusamy and Batra, 
2008; Taipale and Beachy, 2001). A recent study indicated that high expression of Nkx2.2 
inhibits the self-renewal characteristics of glioma TSCs that underlies the high grade tumor 
GBM and switches cell fate towards oligodendroglial differentiation (Muraguchi et al., 
2011). This study is also supported by previous work in which human embryonic stem cells 
(hESCs) were induced by Shh signaling to express Nkx2.2 to form pre-oligodendrocyte 
precursor cells (Hu et al., 2009). These results support a negative role of Nkx2.2 in TSC 
proliferation and suggest that promoting the inhibitory role of Nkx2.2 is a possible 
therapeutic target strategy to cause TSCs to switch their fate from a proliferative nature to a 
differentiated state.  
Interestingly, Nkx2.2 is positively regulated by the graded expression of Shh in neural tube 
development (Briscoe et al., 2000). However, its expression pattern in medulloblastoma, 
astrocytoma and neuroblastoma cell lines and primary tumor samples indicates that it may 
be down-regulated at least partially by Shh signaling, although other signaling pathways 
and transcription factors might also play a role (Shahi et al., 2010; Shahi et al., 2011). 
Regardless, its high expression in low grade astrocytic tumors compared to high grade 
tumors suggest that it would be a good marker for the prognosis of patients to define their 
astrocytic tumor grade (Riemenschneider et al., 2004).   
3.2 Pax6 
Pax6 (paired box gene 6) is a homeodomain transcription factor of which there are 9 
members in this family (Pax1-9). Pax6 is highly conserved in vertebrates and is the most 
studied among the Pax family members for its vital role in neuronal fate determination 
(Mansouri et al., 1996). The vertebrate Pax6 gene encodes three isoforms: canonical Pax6, 
Pax6(5a) and Pax6(PD). The canonical Pax6 has a paired domain (PD) at the N-terminus 
connected via a linker region to the paired type homeodomain (HD). The C-terminus 
contains a proline/serine/theronine (P/S/T) domain. Both PD and HD domains bind to 
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DNA whereas the P/S/T domain has transactivation activity.  Isoform Pax6 (5a) is formed 
with the insertion of 14 residues in the PD, which affects its DNA binding activity. The 
linker region encodes three alternative translation start codons to generate Pax6 isoforms 
known as Pax6 (PD) or pairless isoforms that lack a PD.  
3.2.1 Role of Pax6 in nervous system development 
Pax6 plays a crucial role for the establishment of ventral progenitors and specification of the 
ventral interneuron and motor neuron cell fates in response to graded Shh signaling in the 
ventral spinal cord and hindbrain. There is a low-to-high gradient of Pax6 expression from 
ventral to dorsal in the ventral neural tube in response to graded Shh signaling (Ericson et 
al., 1997). Interestingly, when Pax6 expression is suppressed during Shh signaling, 
expression of other transcription factors appears in the neural tube for specification of 
ventral neurons. After the closure of the neural tube, progenitors are destined to become 
forebrain, midbrain or hindbrain and the demarcation boundary is determined by the 
graded expression pattern of Pax6 (Mastick et al., 1997). 
3.2.2 Role of Pax6 in brain cancer 
Pax6 contributes significantly to neurogenesis and it is expressed throughout the ventricular 
zone and in the external granular layer of the developing cerebellum. High expression of 
Pax6 in transformed rat fibroblasts suggests that it might function as a proto-oncogene 
(Maulbecker and Gruss, 1993). Furthermore, Pax6 showed high expression in 78% of 
medulloblastoma samples (Kozmik et al., 1995). In glioma tumor samples, expression of 
Pax6 was high in low grade tumors (class III-anaplastic astrocytoma) and low in high grade 
class IV-GBM (Zhou et al., 2003). Zhou and colleagues suggest that high expression of Pax6 
is favorable for patient survival compared to low expression, indicating that Pax6 would be 
a good prognostic marker for the transition of low grade to high grade glioma. In a recent 
study, Shahi and colleagues showed that Pax6 expression is regulated by Shh-Gli1 signaling 
in medulloblastoma and astrocytoma cell lines and primary tumor samples (Shahi et al., 
2010). Knockdown of Gli1 in medulloblastoma cells led to decreased Pax6 expression 
compared to control negative siRNA (Shahi et al., 2010), suggesting that Gli1 upregulates 
Pax6 expression in medulloblastoma. Interestingly, medulloblastoma cell lines and primary 
tumor samples showed high expression of Pax6 compared to normal control samples (Shahi et 
al., 2010). Similarly, expression of Pax6 in siRNA-mediated Gli1 knockdown in astrocytoma 
cells led to increased Pax6 expression compared to control negative siRNA (Shahi et al., 2010), 
suggesting that Gli1 might also downregulate Pax6 expression in astrocytoma. Moreover, most 
astrocytoma and primary tumor samples showed low expression of Pax6 compared to normal 
controls (Shahi et al., 2010), supporting this possibility. Intriguingly, this differential regulation 
of Pax6 expression in medulloblastoma and astrocytoma cells suggests that Shh signaling 
elicits distinct outcomes for the growth of these tumors (Shahi et al., 2010). In neuroblastoma 
cell lines, Pax6 expression was low compared to normal control samples (Shahi et al., 2011). 
Moreover, another independent study revealed that Pax6 behaves like a tumor suppressor 
gene to inhibit the invasiveness of glioma tumors (Mayes et al., 2006). Pax6 was found to 
contain a hemizygous deletion in its 5’-region in subependymoma tumor (Maekawa et al., 
2010), suggesting that Pax6 may switch between an oncogene and tumor suppressor and that 
this switching activity is variable among tumors. In favor of this hypothesis, another 
transcription factor, Atoh1 (discussed below), behaves as an oncogene in medulloblastoma 
and a tumor suppressor gene in colorectal cancer and Merkel cell carcinoma (Bossuyt et al., 
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2009; Flora et al., 2009). Atoh1 is regulated by different signaling pathways in these tumors and 
its differential regulation is thought to underlie its onocogenic or tumor suppressive activity 
(Bossuyt et al., 2009; Flora et al., 2009). Therefore, Pax6 might only be a good therapeutic target 
in tumor types for which it behaves as an oncogene such as medulloblastoma.  
3.2.2 Role of Pax6 in stem cells 
Treatment of embryonic stem cells with the soluble signaling molecules BMP4 and Wnt3a 
induced the generation of cerebellar granule and Purkinje cell fates (Su et al., 2006). Pax6 
expression was correlated with these differentiated cells (Su et al., 2006), suggesting that 
Pax6 functions to promote cerebellar cell fate and thus might play a role in medulloblastoma 
biogenesis. Pax6 also plays an indispensable role in the proliferation and expansion of the 
adult mammalian retinal stem cells (Xu et al., 2007). Pax6 is also important for the 
specification of neuroectoderm (NE) from human embryonic stem cells (hESCs) (Zhang et 
al., 2010). Moreover, overexpression of the isoforms Pax6 and Pax6 (5a) but not Pax6 (PD) 
initiate differentiation of hESCs, although, Pax6 appears to be the main factor to determine 
the NE specification (Zhang et al., 2010). Interestingly, during the specification of NE from 
hESCs, Pax6 inhibits the expression of pluripotent genes; however, the mechanism of this 
inhibition is not known (Zhang et al., 2010). It would be intriguing to explore the role of 
specific Pax6 isoforms in brain tumorigenesis and the contribution of these isoforms to the 
stem cell origin of brain tumors.    
4. Transcription factors involved in sonic hedgehog signal transduction in 
cerebellum 
In the cerebellum, Shh is produced by Purkinje neurons to promote proliferation of GNPs 
during the first week of postnatal development (Wechsler-Reya and Scott, 1999). Shh 
signalling regulates proliferation of GNPs in part via expression of the bHLH (basic helix-
loop-helix) transcription factor Nmyc (Kenney et al., 2003; Knoepfler et al., 2002; Oliver et 
al., 2003). Mutations in the Shh pathway are thought to underlie the etiology of 
medulloblastoma that arise from transformed GNPs that fail to cease proliferation during 
development (Wechsler-Reya and Scott, 2001). Interestingly, recent studies have implicated 
two additional transcription factors, Atoh1 (formerly known as Math1) and Mxd3 (formerly 
known as Mad3) in the Shh signalling pathway that regulate GNP proliferation and 
medulloblastoma biogenesis. 
4.1 Atoh1 
Atonal (Atoh1) was originally identified in Drosphila and is highly conserved (other known 
names; Hath1, Math1 and bHLHa14). Atoh1 belongs to the family of bHLH transcription 
factors. The protein consists of a basic domain that recognizes specific E-box sequences 
(5’CANNTG-3’) while the two helices interact with other bHLH protein to form 
heterodimers (Krizhanovsky et al., 2006). Atoh1 plays a key role in specification of cerebellar 
cell fates (Ben-Arie et al., 1996). In the past few years, evidence has been mounting for a role 
of this gene in cerebellar brain tumor development. 
4.1.1 Role of Atoh1 in nervous system development 
The role of Atoh1 in cerebellum is well defined and its regulated expression is important for 
granule cell development (Ben-Arie et al., 1997). Mice lacking Atoh1 fail to form granule 
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cells and are born with a cerebellum that is devoid of an external germinal layer (Ben-Arie et 
al., 1997). Overexpression of Atoh1 interferes with differentiation and causes irregularity in 
the maturation of granule cells (Helms et al., 2001). Interestingly, expression of Atoh1 and 
Neurogenin (another bHLH transcription factor) sub-divides the lower rhombic lip into 
discrete presumptive cell fates and this subdivision is dependent on Pax6 expression 
(Landsberg et al., 2005). The phenotype of Atoh1 overexpressing transgenic mice indicates 
that Atoh1 downregulates expression of Pax6 (Helms et al., 2001). Moreover, misexpression 
of Atoh1 in neural precursors is lethal for the proper development of central nervous system 
(Isaka et al., 1999).  
4.1.2 Role of Atoh1 in brain tumors 
Atoh1 plays a critical role in the coordination of proliferation and differentiation of GNPs 
(Ben-Arie et al., 1997). Therefore, this transcription factor might also be involved in 
medulloblastoma tumorigenesis. In support of this possibility, double mutant mice of poly 
[ADP-ribose] polymerase 1(PARP-1)-/-/p53-/- mice developed medulloblastoma with high 
expression of Atoh1 (Tong et al., 2003), suggesting a role as an oncogene. Interestingly, the 
expression pattern of Atoh1 is distinct in adult and childhood medulloblastoma. In adult 
medulloblastoma, Atoh1 is expressed at high levels compared to childhood 
medulloblastoma (Salsano et al., 2004). The origin of these two categories of 
medulloblastomas is controversial; however, its expression provides further support for the 
role of Atoh1 in medulloblastoma development. Atoh1 is regulated by Shh signaling in 
GNPs (Kenney and Rowitch, 2000) and its expression is downregulated upon Shh signaling 
inhibition (Romer et al., 2004), suggesting that Atoh1 might function in medulloblastoma 
development. Indeed, deletion of Atoh1 disrupts Shh signaling in the developing 
cerebellum and prevents medulloblastoma (Flora et al., 2009), supporting an oncogenic role. 
Interestingly, Atoh1 appears to act directly on the Gli2 transcription factor in the Shh 
signaling pathway to regulate medulloblastoma biogenesis (Flora et al., 2009). It is well 
known that Atoh1 binds to E-box elements within target genes and accordingly Atoh1 binds 
to E-box sequences located in the second intron of Gli2 (Flora et al., 2009). This finding 
represents a new paradigm of the role of Shh signaling in cerebellum and medulloblastoma 
because thus far, Gli1 has been thought to be the major transcription factor of the Shh 
pathway. Gli2 was considered a secondary transcription factor that acts as an activator only 
the absence of Gli1 (Bai and Joyner, 2001). The regulation of Gli2 by Atoh1 suggests the 
possibility that either Atoh1 acts on Gli2 in a Gli1-independent manner or that Gli1 regulates 
the expression of Atoh1 and subsequently Atoh1 acts on Gli2 to promote tumorigenesis.  
Ayrault and colleagues demonstrated that co-expression of Atoh1 and Gli1 in primary 
GNPs cells from postnatal cerebella of healthy C57BL/6 mice transformed into TSCs 
(Ayrault et al., 2010). Less than 200 TSCs were capable to induce medulloblastoma in the 
brain of transplanted naïve mice (Ayrault et al., 2010), suggesting that both Atoh1 and Gli1 
cooperate to transform GNPs into TSCs. However, Ayrault and colleagues were unable to 
see the induction of Gli2 expression in response to Atoh1 induced expression in primary 
GNPs in contrast to Flora and colleagues. The authors suggest that this discrepancy is due to 
different genetic models for their experiments and warrants further research into the 
interaction of Atoh1 with Shh mediated transcription factors Gli1 and Gli2 in the 
development of medulloblastoma. 
Although it has been suggested that Atoh1 acts as an oncogene and a possible target of Shh 
signaling to promote medulloblastoma development, it is important to note that other 
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studies suggest that Atoh1 functions as a tumor suppressor gene in other cell types. For 
example, Atoh1 regulates proliferation and apoptosis in colorectal cancer and Markel cell 
carcinoma with the induction of Jun N-terminal kinase (Ntrk1) signaling pathway (Bossuyt 
et al., 2009). 
4.1.3 Role of Atoh1 in stem cells  
Many markers have been determined for the identification of TSCs including CD133, Nestin 
and BMI-1. Cells expressing these selective markers have the capability to generate tumors 
when xenotranplanted into nude mice. Among these markers, CD133+ expressing cells are 
considered potent medulloblastoma propagating cells. However, a recent study showed that 
Atoh1+ and CD15+/SSEA-1 expressing cells have a higher-fold capability of generating 
medulloblastoma in Ptch1 mutant mice compared to Atoh1-/CD15- cells (Read et al., 2009).  
Intriguingly, CD133+ cells were unable to generate medulloblastoma in Ptch1 mutant mice 
(Read et al., 2009), suggesting that cells expressing high Atoh1+ and CD15+ are specified to 
promote proliferation and to inhibit apoptosis and differentation. Thus, it will be intriguing 
to understand how Atoh1 regulates TSCs that give rise to medulloblastoma.  
4.2 Mxd3 
Mxd3 (previously known as Mad3) is a member of the bHLH transcriptional regulators 
(Hurlin et al., 1995) to which Nmyc also belongs. In the classical model, Myc and Mad 
proteins form heterodimers with the cofactor Max and bind to E-box sequences to activate 
or repress, respectively, transcription (Grandori et al., 2000). Thus, it has long been thought 
that Mad/Max complexes function to antagonize Myc/Max complexes by competitive 
binding to DNA and the promotion to a Mad-dependent differentiation cell state from a 
Myc-dependent proliferative state. Myc is an established oncogene; thus, Mad proteins were 
originally hypothesized to function as tumor suppressor genes. However, recent studies for 
Mxd3 challenge the current model. 
4.2.1 Role of Mxd3 in nervous system development 
Mxd3 is transiently upregulated in GNPs during postnatal cerebellum development and it 
fails to be downregulated in weaver mice in which GNPs fail to exit the cell cycle (Diaz et al., 
2002). In cultured GNPs, Mxd3 is essential for Shh-dependent GNP proliferation and Mxd3 
is upregulated in response to Shh signaling (Yun et al., 2007). Mxd3 regulates GNP 
proliferation in part via expression of Nmyc (Yun et al., 2007). Intriguingly, Mxd3 is 
predicted to interact directly with Nmyc to promote GNP proliferation (Barisone et al., 
2008), suggesting that Mxd3 and Nmyc function as part of a feedback loop to regulate GNP 
proliferation. Similar to other Mad family proteins, mice with a targeted deletion of Mxd3 
are viable; however, Mxd3 null mice exhibit increased sensitivity to radiation-induced 
apoptosis (Queva et al., 2001). The effect of Mxd3 deletion in postnatal cerebellum 
development was not explored in this mouse line. Interestingly, Mxd3 expression in 
immature B cells has been shown to induce cell proliferation without differentiation, a 
phenotype of leukemia (Gore et al., 2010), suggesting that Mxd3 might also regulate 
proliferation of other types of cancer cells. 
4.2.2 Role of Mxd3 in brain cancer 
Like Nmyc, Mxd3 is upregulated in tumors and pre-tumor cells from Ptch1 heterozygous 
mice (Yun et al., 2007) and Mxd3 is expressed in human brain tumors including 
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glioblastoma and medulloblastoma (Barisone et al., 2008).  Together, these studies suggest 
that Mxd3 might also function with Nmyc to regulate tumor biogenesis. Furthermore 
research is required to address this intriguing possibility. 
4.2.3 Role of Mxd3 in stem cells 
Mxd3 has not been studied extensively and there are no published reports regarding a role 
for Mxd3 in regulation of stem cells. However, given the fact that Mxd3 and Nmyc function 
together to regulate GNP proliferation and are predicted to physically associate with each 
other, it is likely that Mxd3 functions with Nmyc to regulate stem cell proliferation. 
Additional experiments are necessary to test this interesting possibility. 
 
Location Function Pathway References 
Ventral progenitors 




Ericson et al., 1997; 




Tumor suppressor Sonic hedgehog 
Riemenschneider et al., 
2004; Shahi et al., 2010 
Medulloblastoma Oncogene Sonic hedgehog Shahi et al., 2010 
Neuroblastoma Tumor suppressor Sonic hedgehog Shahi et al., 2010 
Human embryonic 
stem cells 
Transcription factor Sonic hedgehog Hu et al., 2009 
Oligodendroglial cells Transcription factor Sonic hedgehog 
Danesin et al., 2006; 
Muraguchi et al., 2010 
Table 1. Summary of Nkx2.2 function in neural progenitor cells and tumors. 
 
Location Function Pathway References 
Ventral progenitors 




Ericson et al., 1997 
Medulloblastoma Oncogene Sonic hedgehog 
Kozmik et al., 1995; Shahi 
et al., 2010 
Glioma Tumor suppressor Sonic hedgehog 
Zhou et al., 2003; Mayes 
et al., 2006; Shahi et al., 
2010 
Neuroblastoma Tumor suppressor Sonic hedgehog Shahi et al., 2011 
Subependymoma 
tumors 
Tumor suppressor PTEN, SOX Maekawa et al., 2010 
Embryonic stem cells Transcription factor 
BMP4, Wnt3a, 
Atoh1 
Sue et al., 2006; 
Zhang et al., 2010 
Retinal stem cells Transcription factor 
Sonic hedgehog, 
Sufu 
Xu et al., 2007; 
Cwinn et al., 2011 
Table 2. Summary of Pax6 function in neural progenitor cells and tumors 
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Location Function Pathway References 
Cerebellum Transcription factor 
Sonic hedgehog 
Pax6 
Ben-Arie et al., 1997; 
Kenny and Rowitch 2000; 
Helms et al., 2006; 




Tong et al., 2003; 
Salsano et al., 2004; 
Briggs et al., 2008; 
Flora et al., 2009 
Tumor stem cells Transcription factor Sonic hedgehog 
Ayrault et al., 2010; 
Read et al., 2009 
Neural stem cells Transcription factor Sonic hedgehog 
Isaka et al., 1999; 
Hu et al., 2010 
Colorectral cancer 





Bossuyt et al., 2009 
Table 3. Summary of Atoh1 function in neural progenitor cells and tumors 
 
Location Function Pathway References 
Neural progenitor cells Transcription factor Unknown Queva et al., 2001 
Cerebellar granule cell 
precursors 
Transcription factor Sonic hedgehog Yun et al., 2007 
Medulloblastoma Oncogene Sonic hedgehog 
Yun et al., 2007; 
Barisone et al., 2008 
Immature B cells Transcription factor Id2 Gore et al., 2010 
Table 4. Summary of Mxd3 function in neural progenitor cells and tumors 
5. Conclusion  
While many questions still remain, our understanding of the pediatric brain tumor 
medulloblastoma has become clearer in the past few years. Mounting evidence indicates 
that TSCs are the major contributor to propagate medulloblastoma and that there are many 
pathways that contribute to TSC maintenance. However, the precise mechanism by which 
these TSCs are regulated by these signaling pathways to promote tumorigenesis is not well 
understood. Therefore, additional studies are warranted to understand these pathways. 
However, the identification of new transcription factors that contribute to TSC proliferation 
and tumor biogenesis is a major advance in our understanding of this disease. These new 
transcription factors represent exciting new therapeutic targets for treatment since it is likely 
that a multitude of downstream molecules can be targeted with a single drug. 
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